- Tempus AI (TEM) reported a 35.8% increase in Q4 2024 revenue, reaching $200.7 million.
- Genomics revenue grew by 30.6% to $120.4 million, while data and services revenue increased by 44.6% to $80.2 million.
- For 2025, Tempus AI anticipates a 79% annual growth in revenue to $1.24 billion.
Tempus AI, Inc. (NASDAQ: TEM), a leader in AI-driven precision medicine, released its fourth-quarter and full-year 2024 financial results, showcasing strong growth across key business sectors. The company declared a 35.8% year-over-year revenue increase for Q4 2024, totaling $200.7 million, driven by significant advancements in its genomics and data services divisions.
The Genomics division generated $120.4 million in Q4 2024, marking a 30.6% increase in revenue, alongside a 22.5% unit growth year-over-year. The data and services segment achieved a remarkable 44.6% surge in revenue, reaching $80.2 million for the quarter. Overall, Tempus AI reported a 49.7% increase in gross profit, which amounted to $122.1 million in Q4, primarily led by the data and services sector.
For the full year 2024, Tempus AI achieved $693.4 million in revenue, reflecting a 30.4% growth from the previous year. The company ended the year with a total remaining contract value of $940 million and a net revenue retention rate of 140%. Despite a net loss of ($705.8 million), largely due to the $547.7 million in stock compensation expenses, Tempus AI remains optimistic about its future.
Looking ahead, the company increased its 2025 revenue guidance to $1.24 billion, projecting a 79% annual growth rate following the acquisition of Ambry Genetics. Tempus anticipates an adjusted EBITDA of $5 million for 2025, indicating a substantial improvement of $110 million over 2024. CEO Eric Lefkofsky highlighted the significant role of AI investments in positioning Tempus well for future developments in precision diagnostics.
